Welcome to our dedicated page for Smith & Nephew Plc SEC filings (Ticker: SNNUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Smith & Nephew Plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Smith & Nephew Plc's regulatory disclosures and financial reporting.
Smith & Nephew plc reported that senior executives received new share awards under its RISE Share Plan. On 15 April 2026, the company granted awards over ordinary shares of US$0.20 each to multiple persons discharging managerial responsibilities, including the Chief Executive Officer and Chief Financial Officer, with each listed executive allocated 50 shares at nil cost. The awards form part of the company’s RISE strategy and were granted under the Smith & Nephew plc RISE Share Plan, a sub-plan of the Smith & Nephew plc Restricted Share Plan 2024.
Smith & Nephew plc filed a report noting that Thérèse Esperdy, its Senior Independent Director designate, will join the Board of Rentokil Initial plc as a Non-Executive Director and Chair-designate from 1 July 2026, becoming Chair of the Board on 1 September 2026. The company also highlights that it operates in more than 100 countries with $6.2 billion in annual sales in 2025, supported by around 17,000 employees across its orthopaedics, sports medicine & ENT, and advanced wound management businesses.
Smith & Nephew plc submitted an amended report to clarify how investors can access its 2025 Annual Report, 2026 AGM materials, and proposed new Articles of Association. The company confirms these documents are on the UK National Storage Mechanism and its website, and that hard copies are available free of charge to shareholders and ADS holders upon request to the Company Secretariat in Watford, England.
Smith & Nephew plc reports its updated share capital and voting rights position. As at 31 March 2026, the company has 877,733,750 ordinary shares of US20¢ each in issue, including 23,761,952 held in treasury. The issued share capital with voting rights consists of 853,971,798 ordinary shares, each carrying one vote. Shareholders are directed to use 853,971,798 as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reported that on 23 March 2026 multiple executive and senior managers had share awards vest under its Global Share Plans 2010/2020 and Restricted Share Plan 2024.
Ordinary shares were delivered and portions sold on the London Stock Exchange at £11.938637 to cover tax liabilities, with the balance retained by each participant.
Cevian Capital II GP LTD filed Amendment No. 4 to its Schedule 13D on Smith & Nephew plc, reporting beneficial ownership of 81,687,136 ordinary shares, equal to 9.6% of the outstanding shares. Cevian has sole voting and dispositive power over this entire stake.
Cevian states it bought these shares for the Cevian funds for total consideration of about USD $1,095,708,998, funding the purchases from the funds’ general working capital and paying in British pounds, using an exchange rate of USD $1.32385 per GBP 1.00. The 9.6% figure is based on 849,889,305 ordinary shares outstanding as of February 28, 2026, as reported by the issuer on Form 6-K filed on March 2, 2026.
Smith & Nephew plc submitted a Form 6-K to inform investors that its 2025 Annual Report and related shareholder documents are now available. The company has published the 2025 Annual Report, the Notice of the 2026 Annual General Meeting, the Form of Proxy for the 2026 AGM, and proposed new Articles of Association.
The 2025 Annual Report on Form 20-F was also filed with the SEC on the same day, and all documents are accessible via the UK National Storage Mechanism and the company’s investor relations website.
Smith & Nephew plc filed a Form 6-K stating that it has sent its annual report for fiscal year 2025 to shareholders. The report for the year ended 31 December 2025 is attached as Exhibit 99.1. This filing is primarily administrative, forwarding the full annual report to investors.
Smith & Nephew delivered stronger full-year 2025 results, with revenue rising to $6,164m from $5,810m and operating profit increasing to $794m from $657m. Attributable profit grew to $625m, lifting basic earnings per share to 72.1¢ from 47.2¢.
Growth was broad-based: Orthopaedics revenue reached $2,437m, Sports Medicine & ENT $1,934m, and Advanced Wound Management $1,793m. Established Markets generated $5,161m of revenue and Emerging Markets $1,003m, with US revenue at $3,306m.
Cash generation was robust, with net cash from operating activities of $1,285m. The company invested $433m in capital expenditure and paid equity dividends of $330m, while also spending $502m on share repurchases. Year-end cash and cash equivalents were $553m, and net debt excluding leases was $2,543m.
Deloitte issued unqualified opinions on both the financial statements and internal control over financial reporting. A key audit focus was the valuation of the excess and obsolescence provision for US orthopaedics inventory, reflecting judgement around future product demand.
Smith+Nephew plc reports that its Chief Executive Officer, Deepak Nath, will join the Board of Reckitt Benckiser Group plc as an independent Non-Executive Director with effect from 1 April 2026. The appointment is disclosed in line with UK Listing Rule 6.4.9R(2).
Smith+Nephew is a global medical technology business focused on repairing, regenerating and replacing soft and hard tissue. It employs around 17,000 people, operates in more than 100 countries and generated annual sales of $6.2 billion in 2025 across Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.